Showing results (1-10 of 109) with videos related to
Sort By:
Pageof 11
Hematology/Oncology Clinics of North America|September 10, 2021
Salivary Gland CancersVatche TchekmedyianJournal of Clinical Pharmacy and Therapeutics|November 3, 2021
A Case of Cefepime-Induced Immune ThrombocytopeniaRebecca Bystrom, Minkey Wungwattana, Vatche TchekmedyianJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2019
Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic CarcinomaVatche Tchekmedyian, Eric J Sherman, Lara Dunn, et al.Academic Medicine : Journal of the Association of American Medical Colleges|April 20, 2017
The Effect of Rubric-Guided, Focused, Personalized Coaching Sessions and Video-Recorded Presentations on Teaching Skills Among Fourth-Year Medical Students: A Pilot StudyVatche Tchekmedyian, Helen M Shields, Stephen R Pelletier, et al.Cancer|April 4, 2017
Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinomaMona M Sabra, Eric J Sherman, R Michael TuttleThe Journal of Clinical Endocrinology and Metabolism|September 27, 2018
Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid CancersLara A Dunn, Eric J Sherman, Shrujal S Baxi, et al.Cancers|August 26, 2023
<i>RET</i>-Altered Cancers-A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy ActivityAntoine Desilets, Matteo Repetto, Soo-Ryum Yang, et al.Thyroid : Official Journal of the American Thyroid Association|March 6, 2020
Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted TherapiesTiffany Yeh, Michele Yeung, Eric J Sherman, et al.Oral Oncology|July 11, 2020
Past, present and future of proton therapy for head and neck cancerXingzhe Li, Anna Lee, Marc A Cohen, et al.Nature Medicine|August 24, 2023
Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trialJoris L Vos, Bharat Burman, Swati Jain, et al.Pageof 11